VESPA
13.2.2024 15:01:32 CET | Business Wire | Press release
Vespa, supplier of the leading platform for applications that leverage AI and data online at scale, today announced it has earned recognition as a leader and forward mover in the GigaOm Sonar for Vector Databases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213670564/en/
GigaOm Sonar Reports evaluate technology that is new, interesting, and attractive but poses intrinsic risk when it comes to enterprise adoption. These reports give you the right information at the right time to help plan your strategy. Vespa is positioned as a Leader and Forward Mover in GigaOm's latest report on vector databases. (Graphic: Business Wire)
The research cites Vespa as a platform leader “because of its widespread embedding flexibility, rapid time for updating, and hybrid search capabilities–with neural network rankings. These are critical to maximizing the ROI for vector similarity search engines.”
Andrew Brust, Analyst, GigaOm: “Interest in the vector database market is surging as industries seek advanced AI to manage vast unstructured data. Vespa is well placed in this market with strengths that include model versatility, search flexibility and real-time capabilities.”
Daniel Doro, Director of Engineering, Search, Spotify: “As a reliable and scalable solution, Vespa has been instrumental in enabling Search at Spotify. We look forward to continuing our work with the Vespa team and enabling innovation that will enhance the experience for Spotify listeners.”
Jungwon Byun, COO & Cofounder, Elicit: “Vespa is a battle-tested platform that allows us to integrate keyword and vector search seamlessly. It forms a key part of our AI research solution, guaranteeing precision and rapidity in streamlining research processes. We highly recommend Vespa for its reliability and efficiency.”
Jon Bratseth, CEO and Founder, Vespa: “We are pleased to be recognized as a leader in an emerging, highly relevant, and rapidly growing market. AI is getting significant attention for its role in solving today's data challenges found in eCommerce, digital media, financial services and other industries. Vespa enables organizations to realize this opportunity. GigaOm brings clarity to this crowded and hype laden market.”
In October 2023, Vespa was spun out from Yahoo as an independent company, although the technology has existed for over a decade. Yahoo remains a key investor with Vespa technology underpinning approximately 150 applications that are integral to Yahoo’s operations.
The GigaOm Sonar for Vector Databases can be downloaded here:
https://content.vespa.ai/gigaom-report-2024
About Vespa
Vespa is a platform for applications which leverage AI and data to deliver experiences to end users online in real time, such as search, recommendation, personalization, and retrieval-augmented generation (RAG). Vespa automatically organizes data, inference and logic to allow applications to work with any amount of data, queries, and is available both as a managed service and as open source.
About Elicit
Elicit is the first AI research assistant using language models to automate research workflows like literature review. Over 250,000 researchers in leading academic and industry labs around the world use Elicit every month to summarize papers and extract insights at scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213670564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom